GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PhotoCure ASA (OTCPK:PHCUF) » Definitions » EV-to-EBITDA

PhotoCure ASA (PhotoCure ASA) EV-to-EBITDA : 18.46 (As of May. 26, 2024)


View and export this data going back to . Start your Free Trial

What is PhotoCure ASA EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, PhotoCure ASA's enterprise value is $127.11 Mil. PhotoCure ASA's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $6.88 Mil. Therefore, PhotoCure ASA's EV-to-EBITDA for today is 18.46.

The historical rank and industry rank for PhotoCure ASA's EV-to-EBITDA or its related term are showing as below:

PHCUF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -511.5   Med: -15.58   Max: 1819.39
Current: 18.47

During the past 13 years, the highest EV-to-EBITDA of PhotoCure ASA was 1819.39. The lowest was -511.50. And the median was -15.58.

PHCUF's EV-to-EBITDA is ranked worse than
63.78% of 715 companies
in the Drug Manufacturers industry
Industry Median: 14.42 vs PHCUF: 18.47

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-26), PhotoCure ASA's stock price is $5.95. PhotoCure ASA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $0.017. Therefore, PhotoCure ASA's PE Ratio for today is 350.00.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


PhotoCure ASA EV-to-EBITDA Historical Data

The historical data trend for PhotoCure ASA's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PhotoCure ASA EV-to-EBITDA Chart

PhotoCure ASA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.43 -372.25 154.79 -127.86 24.94

PhotoCure ASA Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -509.75 47.70 51.64 24.94 16.77

Competitive Comparison of PhotoCure ASA's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, PhotoCure ASA's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PhotoCure ASA's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PhotoCure ASA's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where PhotoCure ASA's EV-to-EBITDA falls into.



PhotoCure ASA EV-to-EBITDA Calculation

PhotoCure ASA's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=127.110/6.884
=18.46

PhotoCure ASA's current Enterprise Value is $127.11 Mil.
PhotoCure ASA's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.88 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PhotoCure ASA  (OTCPK:PHCUF) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

PhotoCure ASA's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=5.95/0.017
=350.00

PhotoCure ASA's share price for today is $5.95.
PhotoCure ASA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.017.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


PhotoCure ASA EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of PhotoCure ASA's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


PhotoCure ASA (PhotoCure ASA) Business Description

Traded in Other Exchanges
Address
Hoffsveien 4, Oslo, NOR, 0275
PhotoCure ASA is a Norway-based business group associated with the research, development, production, distribution, marketing, and sales of pharmaceutical products specialty pharmaceutical companies. Its technology platform is focused on the field of photodynamic diagnosis and treatment of cancer. It has two operating segments of the group the Commercial franchise and the Development portfolio. It generates prime revenue from the Commercial franchise segment, which includes Hexvix and Cysview products. Its geographical segments are Nordic countries, Germany, France, Austria, the United Kingdom, Netherlands, Other European countries, and the United States.